May 2024 - We’re delighted to share that the final results of the iCMLf CANDID Study will be presented as a poster at the European Hematology Association (EHA) 2024 Hybrid Congress. The study collected data on over 1000 CML patients across 57 countries, shedding light on the intersection of CML and COVID-19 globally. 

The poster will be presented during the poster session on CML.  Don't miss!
Come and join us on Friday, June 14 from 18.00 - 19.00 CEST at the Poster area in Hall 7.

Coming soon:
EHA 2024: COVID-19 in patients with CML:
Final results from the global observational iCMLf CANDID Study

Poster to be presented at the European Hematology Association (EHA) Hybrid Congress 2024 (Réa D et al.)
Poster session: Chronic myeloid leukemia - Clinical
Date: Friday, June 14, 2024 from 18.00 - 19.00 CEST (Poster Area, Hall 7)

Aim: The study delves into the impact of COVID-19 on patients with CML globally.

Conclusion: The majority of CML patients experienced mild/moderate forms of COVID-19. The COVID-19 severity/mortality rates for patients with CML were lower compared to other hematological malignancies. Factors such as age, comorbidities, and CML phase influenced COVID-19 outcomes.

This research underscores the importance of vaccination for CML patients, emphasising its role in reducing individual risk and disease transmission.

Learn more about other key data that have been presented at major meetings from this important registry here